bioRxivMicrobiologyPreprint
An assessment of Nano-RECall: Interpretation of Oxford Nanopore sequence data for HIV-1 drug resistance testing
K. E. Delaney, T. Ngobeni, C. K. Woods, C. Gordijn, M. Claassen, U. Parikh, P. R. Harrigan, G. U. Van Zyl
Abstract
IntroductionOxford Nanopore Technologies (ONT) offer sequencing with low-capital-layout sequencing options, which could assist in expanding HIV drug resistance testing to resource limited settings. However, sequence analysis remains time time-consuming and reliant on skilled personnel. Moreover, current ONT bioinformatic pipelines provide a single consensus sequence that is not equivalent to Sanger sequencing, as drug resistance is often detected in mixed populations. We have therefore investigated an integrated bioinformatic pipeline, Nano-RECall, for seamless drug resistance of low read coverage ONT sequence data from affordable Flongle or MinION flow cells. MethodsWe compared Sanger sequencing to ONT sequencing of the same HIV-1 subtype C polymerase chain reaction (PCR) amplicons, respectively using RECall and the novel Nano-RECall bioinformatics pipelines. Amplicons were from separate assays a) Applied Biosystems HIV-1 Genotyping Kit (ThermoFisher) spanning protease (PR) to reverse transcriptase (RT) (PR-RT) (n=46) and b) homebrew integrase (IN) (n=21). We investigated optimal read-depth by assessing the coefficient of variation (CV) of nucleotide proportions for various read-depths; and between replicates of 400 reads. The agreement between Sanger sequences and ONT sequences were assessed at nucleotide level, and at codon level for Stanford HIV drug resistance database mutations. ResultsThe coefficient of variation of ONT minority variants plateaued after a read depth of 400-fold implying limited benefit of additional depth and replicates of 400 reads showed a CV of [~]6 % for a representative position. The average sequence similarity between ONT and Sanger sequences was 99.3% (95% CI: 99.1-99.4%) for PR-RT and 99.6% (95% CI: 99.4-99.7%) for INT. Drug resistance mutations did not differ for 21 IN sequences; 16 mutations were detected by both ONT- and Sanger sequencing. For the 46 PR and RT sequences, 245 mutations were detected by either ONT or Sanger, of these 238 (97.1%) were detected by both. ConclusionsThe Nano-RECall pipeline, freely available as a downloadable application on a Windows computer, provides Sanger-equivalent HIV drug resistance interpretation. This novel pipeline combined with a simple workflow and multiplexing samples on ONT flow-cells would contribute to making HIV drug resistance sequencing feasible for resource limited settings.
- organism: human
- assay: long-read sequencing
- research focus: drug response / drug discovery
- approach: deep learning
- approach: statistical model
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Barcoding analysis of HIV drug resistance mutations using Oxford Nanopore MinION (ONT) sequencing
Claudia González, Jessica Góndola, … Alexander A. Martínez·bioRxiv·Mar 5, 2018
- NanoHIVSeq: A Long-Read Bioinformatics Pipeline for High-Throughput Processing of HIV Env Sequences
Zizhang Sheng, Qin Xiao, … Xueling Wu·bioRxiv·Feb 19, 2026
- A comprehensive genomics solution for HIV surveillance and clinical monitoring in a global health setting
David Bonsall, Tanya Golubchik, … Christophe Fraser·bioRxiv·Aug 28, 2018
- Detection of novel HIV-1 drug resistance mutations by support vector analysis of deep sequence data and experimental validation
M. Avino, E. Ndashimye, … A. F. Poon·bioRxiv·Oct 14, 2019
- An Oxford Nanopore Technology-Based Hepatitis B Virus Sequencing Protocol Suitable For Genomic Surveillance Within Clinical Diagnostic Settings.
Derek Tshiabuila, Wonderful Tatenda Choga, … Túlio de Oliveira·International Journal of Molecular SciencesPeer-reviewed·Oct 31, 2024
- OligoSeq: Rapid nanopore-sequencing of single-stranded oligonucleotides
Robert Ramirez-Garcia, Akashaditya Das, … Thomas Heinis·PLoS ONEPeer-reviewed·Sep 3, 2026